Lentiviral gene transfer vectors and their medicinal applications
AssigneesInstitut Pasteur, Centre National De La Recherche Scientifique, Theravectys
InventorsPierre Charneau, Anne-Sophie Beignon, Frederic Philippe Coutant, Karine Courbeyrette
Life of this patent
Estimating the term…
Abstract
The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo.
Claims22
A lentiviral vector particle comprising a nucleic acid comprising a functional lentiviral DNA flap sequence and a β2 microglobulin promoter;
- wherein the lentiviral vector particle is pseudotyped with a vesicular stomatitis virus G protein selected from New Jersey, SVCV, Isfahan, and Cocal strains, and
- wherein the vesicular stomatitis virus G protein is generated in human cells from a nucleic acid sequence that has been codon-optimized for expression in human cells.
Dependencies are inferred from the claim text.